RxDoctor Payments Data

Hector Puig-Ramirez, MD

Pulmonary Disease · Ponce, PRNPI 1467414276

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,079 of the $7,607 with a category attached, or 66.8%. 17 manufacturers reported payments, led by Bayer at 35.9% of the total. Reporting peaked in 2019 at $3,512 and has fallen 87.6% since, to $435 in 2025.

$7,607in general payments, 2019–2025

Across 165 payments — averaging $46.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$3K
  • AstraZeneca$2K
  • GSK$1K
  • Merck$254
  • Sanofi$230
  • United Therapeutics Corporation$228
  • plus $841 from 11 others

What the payments were for

  • Consulting fees$2,21029%
  • Travel & lodging$2724%
  • Food & beverage$5,07967%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,607 in reported general payments places this provider in the 80th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,785
Medicare patients
43
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat13$183,460
Breo ElliptaFluticasone/Vilanterol75$31,887
Albuterol Sulfate HfaAlbuterol Sulfate631$27,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,703
Fluticasone Propionate HfaFluticasone Propionate66$23,132
Wixela InhubFluticasone Propion/Salmeterol97$20,329
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$20,078
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate69$19,235
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,941
SymbicortBudesonide/Formoterol Fumarate48$11,734
Atrovent HfaIpratropium Bromide20$10,370
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,754
Montelukast Sodium564$4,753
Azithromycin468$4,558
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$2,730$183,46013 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$1,437$71,531142 claims
Boehringer IngelheimStiolto Respimat$141$20,07841 claims
AstraZenecaSymbicort, Breztri Aerosphere$1,888$19,48860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →